Syndax Pharmaceuticals Stock Performance
| SNDX Stock | USD 20.22 1.08 5.07% |
On a scale of 0 to 100, Syndax Pharmaceuticals holds a performance score of 8. The entity has a beta of 0.69, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Syndax Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Syndax Pharmaceuticals is expected to be smaller as well. Please check Syndax Pharmaceuticals' potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Syndax Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Syndax Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Syndax Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.38 | Five Day Return 0.85 | Ten Year Return 77.5 | All Time Return 77.5 |
1 | Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 | 11/05/2025 |
2 | JPMorgan Reduces PT on Syndax Pharmaceuticals to 33, Maintains Overweight Rating | 11/17/2025 |
3 | Barclays Raises Syndax PT to 35 on Positive Management Update, Model Rerating | 11/28/2025 |
4 | Disposition of 1224 shares by Goldan Keith A. of Syndax Pharmaceuticals subject to Rule 16b-3 | 12/01/2025 |
5 | Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj Presentations Spanning the Acute Leukemia Treatment Continuum | 12/08/2025 |
6 | Should New Revuforj Leukemia Data From ASH 2025 Require Action From Syndax Pharmaceuticals Investors | 12/09/2025 |
7 | Syndax Pharmaceuticals Buy Rating Reiterated at BTIG Research | 12/12/2025 |
8 | Can Revuforjs Awards Momentum Redefine Syndax Pharmaceuticals Precision Oncology Investment Narrative | 12/16/2025 |
9 | Assenagon Asset Management S.A. Sells 255,848 Shares of Syndax Pharmaceuticals, Inc. SNDX - MarketBeat | 12/19/2025 |
10 | Syndax Pharmaceuticals Sets New 1-Year High Time to Buy | 12/23/2025 |
| Begin Period Cash Flow | 295.6 M | |
| Total Cashflows From Investing Activities | -219.8 M |
Syndax Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,645 in Syndax Pharmaceuticals on October 7, 2025 and sell it today you would earn a total of 377.00 from holding Syndax Pharmaceuticals or generate 22.92% return on investment over 90 days. Syndax Pharmaceuticals is currently generating 0.4019% in daily expected returns and assumes 3.9415% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Syndax, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Syndax Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Syndax Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Syndax Pharmaceuticals, and traders can use it to determine the average amount a Syndax Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.102
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SNDX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Syndax Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Syndax Pharmaceuticals by adding it to a well-diversified portfolio.
Syndax Pharmaceuticals Fundamentals Growth
Syndax Stock prices reflect investors' perceptions of the future prospects and financial health of Syndax Pharmaceuticals, and Syndax Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Syndax Stock performance.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (2.80) % | ||||
| Operating Margin | (1.25) % | ||||
| Current Valuation | 1.4 B | ||||
| Shares Outstanding | 86.91 M | ||||
| Price To Earning | 126.11 X | ||||
| Price To Book | 16.04 X | ||||
| Price To Sales | 16.63 X | ||||
| Revenue | 23.68 M | ||||
| Gross Profit | (133.23 M) | ||||
| EBITDA | (313.82 M) | ||||
| Net Income | (318.76 M) | ||||
| Cash And Equivalents | 350.71 M | ||||
| Cash Per Share | 5.82 X | ||||
| Total Debt | 345.74 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 17.19 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (274.9 M) | ||||
| Earnings Per Share | (3.60) X | ||||
| Market Capitalization | 1.85 B | ||||
| Total Asset | 724.82 M | ||||
| Retained Earnings | (1.22 B) | ||||
| Working Capital | 499.51 M | ||||
| Current Asset | 79.72 M | ||||
| Current Liabilities | 13.32 M | ||||
About Syndax Pharmaceuticals Performance
Evaluating Syndax Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Syndax Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Syndax Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 185.99 | 176.69 | |
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (1.27) | (1.21) |
Things to note about Syndax Pharmaceuticals performance evaluation
Checking the ongoing alerts about Syndax Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Syndax Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Syndax Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 23.68 M. Net Loss for the year was (318.76 M) with loss before overhead, payroll, taxes, and interest of (133.23 M). | |
| Syndax Pharmaceuticals currently holds about 350.71 M in cash with (274.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
| Syndax Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Syndax Pharmaceuticals Sets New 1-Year High Time to Buy |
- Analyzing Syndax Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Syndax Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Syndax Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Syndax Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Syndax Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Syndax Pharmaceuticals' stock. These opinions can provide insight into Syndax Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.